Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

This study has been withdrawn prior to enrollment.
(The treatment planned was determined to be of low feasibility as no subject was found eligible and able to enroll after screening over 30 subjects)
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
Altor Bioscience Corporation Identifier:
First received: November 17, 2011
Last updated: January 2, 2014
Last verified: January 2014
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: November 2013
  Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)